Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Beckman Coulter Diagnostics expands Alzheimer’s portfolio with CE-marked p-Tau217 blood test and new high-specificity research assay

Summary by News Medical
Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Access p-Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline.

1 Articles

News MedicalNews Medical
Center

Beckman Coulter Diagnostics expands Alzheimer’s portfolio with CE-marked p-Tau217 blood test and new high-specificity research assay

Beckman Coulter Diagnostics, a global leader in clinical diagnostics and a Danaher company, today announced it received CE Mark under IVDR for its Access p-Tau217 assay, a blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of cognitive decline.

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

News Medical broke the news in United States on Tuesday, July 7, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Alzheimer's Disease icon

Alzheimer's Disease

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal